Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study.

Lee MR, Wehring HJ, McMahon RP, Linthicum J, Cascella N, Liu F, Bellack A, Buchanan RW, Strauss GP, Contoreggi C, Kelly DL

Schizophrenia research13 Feb 2013Cited by 63 (Europe PMC)

PMID23415472PMCIDPMC4125132DOI10.1016/j.schres.2013.01.001PepBankPUB-23415472

Source link PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In the small group of inpatients with schizophrenia or schizoaffective disorder, adjunctive intranasal oxytocin improved negative symptoms in a secondary analysis.
In plain wordsIn a small group of hospital inpatients with schizophrenia, oxytocin through the nose improved negative symptoms in a secondary analysis.
Peptide
Oxytocin
Outcome
DecreaseNegative symptoms in inpatients (secondary analysis)
Study
n = 12
Comparator
Placebo
Analysis
Secondary
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
20 IU BID · intranasal · 3 weeksAs given in this study (human).
Source sentences
Summary
Secondary analysis shows that intranasal oxytocin improved negative symptoms in the small group of inpatients.
2 context sentences(design, population, supporting numbers)
Summary · context
Individuals with schizophrenia or schizoaffective disorder (n=28; 16 outpatients, 12 inpatients) were randomized to receive adjunctive intranasal oxytocin 20 IU BID or placebo for 3 weeks.
Summary · context
All 28 participants completed the clinical trial.
Report a problemFND-2341547206
02HumanRandomized controlled trialEfficacy outcome
In people with schizophrenia or schizoaffective disorder, adjunctive intranasal oxytocin improved the UPSIT total score compared with placebo from baseline to endpoint.
In plain wordsIn people with schizophrenia, oxytocin through the nose improved smell identification scores more than placebo over three weeks.
Peptide
Oxytocin
Outcome
IncreaseUPSIT total score (olfactory identification)
Study
n = 28
Comparator
Placebo
Outcome group
Sensory perception · Nervous system and cognition
Studied dose
20 IU BID · intranasal · 3 weeksAs given in this study (human).
Source sentences
Summary
Odor identification performance significantly improved on the University of Pennsylvania Smell Identification Test (UPSIT) total score and subscore for pleasant smells. UPSIT score (F=5.20, df=1,23, p=0.032) and subscore for pleasant smells (F=4.56, df=1,23, p=0.044), in patients treated with oxytoc…
2 context sentences(design, population, supporting numbers)
Summary · context
Individuals with schizophrenia or schizoaffective disorder (n=28; 16 outpatients, 12 inpatients) were randomized to receive adjunctive intranasal oxytocin 20 IU BID or placebo for 3 weeks.
Summary · context
All 28 participants completed the clinical trial.
Report a problemFND-2341547201
03HumanRandomized controlled trialEfficacy outcome
In people with schizophrenia or schizoaffective disorder, adjunctive intranasal oxytocin improved the UPSIT subscore for pleasant smells compared with placebo.
In plain wordsIn people with schizophrenia, oxytocin through the nose improved identification of pleasant smells more than placebo.
Peptide
Oxytocin
Outcome
IncreaseUPSIT subscore for pleasant smells
Study
n = 28
Comparator
Placebo
Outcome group
Sensory perception · Nervous system and cognition
Studied dose
20 IU BID · intranasal · 3 weeksAs given in this study (human).
Source sentences
Summary
Odor identification performance significantly improved on the University of Pennsylvania Smell Identification Test (UPSIT) total score and subscore for pleasant smells. UPSIT score (F=5.20, df=1,23, p=0.032) and subscore for pleasant smells (F=4.56, df=1,23, p=0.044), in patients treated with oxytoc…
2 context sentences(design, population, supporting numbers)
Summary · context
Individuals with schizophrenia or schizoaffective disorder (n=28; 16 outpatients, 12 inpatients) were randomized to receive adjunctive intranasal oxytocin 20 IU BID or placebo for 3 weeks.
Summary · context
All 28 participants completed the clinical trial.
Report a problemFND-2341547202
04HumanRandomized controlled trialEfficacy outcome
In people with schizophrenia or schizoaffective disorder, adjunctive intranasal oxytocin did not improve global symptomatology.
In plain wordsIn people with schizophrenia, oxytocin through the nose did not improve overall symptoms.
Peptide
Oxytocin
Outcome
No significant changeGlobal symptomatology
Study
n = 28
Comparator
Placebo
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
20 IU BID · intranasal · 3 weeksAs given in this study (human).
Source sentences
Summary
Global symptomatology as well as positive and negative symptoms were not improved by intranasal oxytocin.
2 context sentences(design, population, supporting numbers)
Summary · context
Individuals with schizophrenia or schizoaffective disorder (n=28; 16 outpatients, 12 inpatients) were randomized to receive adjunctive intranasal oxytocin 20 IU BID or placebo for 3 weeks.
Summary · context
All 28 participants completed the clinical trial.
Report a problemFND-2341547203
05HumanRandomized controlled trialEfficacy outcome
In people with schizophrenia or schizoaffective disorder, adjunctive intranasal oxytocin did not improve positive symptoms.
In plain wordsIn people with schizophrenia, oxytocin through the nose did not improve positive symptoms.
Peptide
Oxytocin
Outcome
No significant changePositive symptoms
Study
n = 28
Comparator
Placebo
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
20 IU BID · intranasal · 3 weeksAs given in this study (human).
Source sentences
Summary
Global symptomatology as well as positive and negative symptoms were not improved by intranasal oxytocin.
2 context sentences(design, population, supporting numbers)
Summary · context
Individuals with schizophrenia or schizoaffective disorder (n=28; 16 outpatients, 12 inpatients) were randomized to receive adjunctive intranasal oxytocin 20 IU BID or placebo for 3 weeks.
Summary · context
All 28 participants completed the clinical trial.
Report a problemFND-2341547204
06HumanRandomized controlled trialEfficacy outcome
In people with schizophrenia or schizoaffective disorder, adjunctive intranasal oxytocin did not improve negative symptoms overall.
In plain wordsIn people with schizophrenia, oxytocin through the nose did not improve negative symptoms overall.
Peptide
Oxytocin
Outcome
No significant changeNegative symptoms
Study
n = 28
Comparator
Placebo
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
20 IU BID · intranasal · 3 weeksAs given in this study (human).
Source sentences
Summary
Global symptomatology as well as positive and negative symptoms were not improved by intranasal oxytocin.
2 context sentences(design, population, supporting numbers)
Summary · context
Individuals with schizophrenia or schizoaffective disorder (n=28; 16 outpatients, 12 inpatients) were randomized to receive adjunctive intranasal oxytocin 20 IU BID or placebo for 3 weeks.
Summary · context
All 28 participants completed the clinical trial.
Report a problemFND-2341547205
07HumanRandomized controlled trialSafety outcome
In people with schizophrenia or schizoaffective disorder, intranasal oxytocin was well tolerated during the three-week trial.
In plain wordsIn people with schizophrenia, oxytocin through the nose was well tolerated during the three-week trial.
Peptide
Oxytocin
Outcome
No significant changeTolerability over 3 weeks
Study
n = 28
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
20 IU BID · intranasal · 3 weeksAs given in this study (human).
Source sentences
Summary
Intranasal oxytocin was well tolerated during the three week trial.
2 context sentences(design, population, supporting numbers)
Summary · context
Individuals with schizophrenia or schizoaffective disorder (n=28; 16 outpatients, 12 inpatients) were randomized to receive adjunctive intranasal oxytocin 20 IU BID or placebo for 3 weeks.
Summary · context
All 28 participants completed the clinical trial.
Report a problemFND-2341547207

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT00884897

Oxytocin and Social Cognition in Schizophrenia

University of Maryland, Baltimoren = 28Jan 2010 to Jan 2012

Social Cognition · Social Anxiety · Emotional Intelligence

Trial page ClinicalTrials.govUpdated 2 Oct 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 01:30 UTC
Study results updated
Version 1
9 Oct 2026, 02:49 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.